Simon Melov

Part of Insmed, Inc., Celtrix Pharmaceuticals, Inc. researches and develops potential therapeutic products. The company is based in Santa Clara, CA.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Buck Institute for Research on Aging operates independent research institute for connection between aging and chronic disease. The company is headquartered in Novato, CA.

The Biotechnology Institute is a non-profit organization, which engages in designing and managing programs about biotechnology research. Its programs include BioGENEius Challenges, leadership awards, and Adopt-A-School. The company was founded in 1998 and is headquartered in Washington, DC.

Biotherapeutics, Inc. operates as a pre-clinical stage company which develops small-molecule drugs to treat inflammation and type 2 diabetes. Its scientific foundation is anchored on informatics and computer modeling-enabled drug development with significant animal pharmacology validation. The company was founded by Josep Bassaganya-Riera in 2008 and is headquartered in Blacksburg, VA.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.